RICHMOND, Va., January 14, 2026 – Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced a major advancement in AI-driven Active ...
Enveda has been using AI to power its drug discovery platform for several years. The company injected $230 million into ...
The global high potency API contract manufacturing market, valued at USD 8 billion in 2022, is poised for robust growth, with projections to reach USD 16 billion by 2032. This remarkable expansion, ...
(MENAFN- IMARC Group) Setting up an API Manufacturing facility necessitates a detailed market analysis alongside granular insights into various operational aspects, including unit processes, raw ...
(MENAFN- IMARC Group) An API (Active Pharmaceutical Ingredient) is the biologically active component of a drug that produces the intended therapeutic effect. It is the essential substance in medicines ...
The global high potency API contract manufacturing market, valued at USD 8 billion in 2022, is poised for robust growth, with projections to reach USD 16 billion by 2032. This remarkable expansion, ...
Bristol-Myers Squibb (BMS) has agreed to sell its small-molecule active pharmaceutical ingredient (API) manufacturing facility in Swords, Ireland, to Seoul, South Korea-based contract development and ...
MILAN, Sept. 3, 2018 /CNW/ - Olon S.p.A., a world leading Active Pharmaceutical Ingredients (API) contract development and manufacturing organization (CDMO) and generics supplier, announced today the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback